Form 4: Dynavax VP's Stock Transactions Post-Merger Agreement

Joseph Anthony Metzinger, Dynavax Technologies Corp.'s VP, Chief Accounting Officer, reported accelerated RSU vesting and subsequent stock transactions following a merger agreement with Sanofi.

Summary

• Joseph Anthony Metzinger, VP, Chief Accounting Officer of Dynavax Technologies Corp. (DVAX), reported transactions related to his beneficial ownership.
• On December 23, 2025, 12,727 restricted stock units (RSUs) vested due to acceleration approved by the Board of Directors.
• This acceleration was in connection with an Agreement and Plan of Merger dated December 23, 2025, by and among Dynavax, SANOFI, and Samba Merger Sub, Inc.
• Each RSU represents a contingent right to receive one share of Dynavax's common stock.
• Following the vesting, 12,727 shares of common stock were acquired by Mr. Metzinger.
• On December 24, 2025, 5,598 shares were disposed of by the Issuer to satisfy tax withholding requirements at a price of $15.38 per share.
• Mr. Metzinger's direct beneficial ownership of common stock increased by 7,129 shares (12,727 acquired 5,598 disposed).
• His remaining derivative securities (RSUs) are 25,455.
• The RSUs were originally granted on May 12, 2025, and were scheduled to vest over three years, with 1/3 vesting on each anniversary of May 12, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual report of insider transactions and a corporate event (merger agreement). It does not inherently convey positive or negative sentiment about the company's operational performance, but rather details a consequence of a significant strategic decision.

Positives

• Accelerated vesting of 12,727 restricted stock units for the VP, Chief Accounting Officer.
• The RSU acceleration was triggered by a merger agreement, indicating a significant corporate event for Dynavax.

Negatives

• 5,598 shares were withheld by the Issuer to cover tax obligations, reducing the net shares received by the executive.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports insider transactions. Risks associated with the merger itself would be detailed in other corporate filings.

Future Outlook

The filing indicates a merger agreement with Sanofi, which will significantly impact the company's future structure and operations. However, specific forward-looking statements or guidance beyond the merger's existence are not provided in this Form 4.

Industry Context

The reported transactions are a direct consequence of a merger agreement between Dynavax Technologies Corp. and Sanofi. Such mergers are significant events in the biotechnology and pharmaceutical industry, often driven by strategic portfolio expansion, market consolidation, or access to new technologies/pipelines. The acceleration of executive equity vesting is a common provision in change-of-control clauses within executive compensation agreements.

Comparison to Industry Standards

• The acceleration of restricted stock unit vesting upon a change of control, such as a merger, is a standard practice in executive compensation agreements across various industries, including biotechnology. This mechanism is designed to ensure executives are compensated for their contributions up to the point of acquisition and to align their interests with shareholders during a sale process. Specific comparable companies or projects are not detailed in this filing, as it focuses on an individual's transaction.

Corporate Governance

Related Party Transactions

• The filing explicitly mentions an 'Agreement and Plan of Merger' by and among the Issuer (Dynavax), SANOFI, and Samba Merger Sub, Inc. This merger agreement itself constitutes a significant transaction that triggered the RSU acceleration.

Stakeholder Impact

• Shareholders: The merger agreement with Sanofi, which triggered the RSU acceleration, is a significant event that will directly impact shareholders, likely through an acquisition price or exchange ratio.
• Executive (Joseph Anthony Metzinger): Directly impacted by the accelerated vesting and subsequent stock transactions, resulting in a net increase in common stock ownership.

Next Steps

• The completion of the merger with Sanofi, as indicated by the 'Agreement and Plan of Merger'.
• Further details regarding the merger terms and implications would be expected in other SEC filings.

Key Dates

Keywords

Dynavax Technologies Corp., DVAX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Merger Agreement, Executive Compensation, Stock Acquisition, Tax Withholding, Sanofi